Q1 EPS Estimate for USANA Health Sciences Lowered by Analyst

Key Points

• Sidoti cut its Q1 2027 EPS estimate for USANA Health Sciences to $0.24 from $0.28.
• USANA’s latest quarter fell short of expectations, reporting an EPS loss of $0.11 versus consensus earnings of $0.11 and revenue of $205.89 million versus estimates of $217.42 million.
• Analyst sentiment is bearish: MarketBeat reports a consensus “Sell” rating, including a recent Zacks Research downgrade from “Hold” to “Strong Sell.”

USANA Health Sciences, Inc. (NYSE:USNA - Free Report) - Research analysts at Sidoti reduced their Q1 2027 EPS estimates for USANA Health Sciences in a research note issued to investors on Thursday, November 5th. Sidoti analyst A. Lebiedzinski now expects that the company will post earnings of $0.24 per share for the quarter, down from their prior estimate of $0.28. The consensus estimate for USANA Health Sciences' current full-year earnings is $0.55 per share. Sidoti also issued estimates for USANA Health Sciences' Q2 2027 earnings at $0.34 EPS, Q3 2027 earnings at $0.31 EPS, Q4 2027 earnings at $0.36 EPS, Q1 2028 earnings at $0.35 EPS, Q2 2028 earnings at $0.44 EPS, Q3 2028 earnings at $0.42 EPS and FY2028 earnings at $1.68 EPS.

USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its earnings results on Tuesday, November 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.11 by ($0.22). The firm had revenue of $205.89 million during the quarter, compared to analyst estimates of $217.42 million. USANA Health Sciences had a negative net margin of 2.34% and a positive return on equity of 3.56%.

Several other research firms have also recently weighed in on USNA. Wall Street Zen downgraded USANA Health Sciences from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Zacks Research downgraded USANA Health Sciences from a "hold" rating to a "strong sell" rating in a research report on Wednesday, November 4th. Finally, Weiss Ratings reiterated a "sell (d)" rating on shares of USANA Health Sciences in a report on Monday, September 21st. Two equities research analysts have rated the stock with a Sell rating. Based on data from MarketBeat, the company has a consensus rating of "Sell".

USANA Health Sciences Stock Performance

Shares of NYSE:USNA opened at $13.62 on Monday. The stock's 50-day moving average is $14.60 and its 200-day moving average is $17.95. The company has a market cap of $251.71 million, a P/E ratio of -11.85, a P/E/G ratio of 2.07 and a beta of 0.66. USANA Health Sciences has a 52-week low of $12.57 and a 52-week high of $23.59.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in USANA Health Sciences during the second quarter worth about $33,182,000. Pzena Investment Management LLC bought a new position in USANA Health Sciences during the second quarter valued at about $25,739,000. Nantahala Capital Management LLC bought a new position in USANA Health Sciences during the second quarter valued at about $17,295,080. Algert Global LLC increased its stake in USANA Health Sciences by 91.8% during the second quarter. Algert Global LLC now owns 131,758 shares of the company's stock valued at $2,813,000 after acquiring an additional 63,074 shares during the period. Finally, Empowered Funds LLC acquired a new position in USANA Health Sciences in the 2nd quarter valued at approximately $1,500,000. Institutional investors and hedge funds own 54.25% of the company's stock.

Key USANA Health Sciences News

Here are the key news stories impacting USANA Health Sciences this week:

• Positive Sentiment: Sidoti raised its Q4 2026 EPS estimate slightly, to $0.12 from $0.11, though this was outweighed by reductions to other forecasts.
• Neutral Sentiment: USANA updated its fiscal 2026 earnings guidance, and its Q3 2026 earnings-call transcript was published. The supplied headlines do not provide details of the guidance update. USANA fiscal 2026 guidance update
• Negative Sentiment: Zacks Research downgraded USANA from “hold” to “strong sell,” a notably bearish change in analyst sentiment. Zacks downgrade report
• Negative Sentiment: Sidoti cut its FY2026 EPS estimate to $0.55 from $0.76, and lowered its FY2027 forecast to $1.59 from $1.77. It also reduced estimates for Q1–Q3 2027, signaling weaker expected earnings.
• Negative Sentiment: The supplied earnings background also shows USANA’s latest quarter missed analyst expectations for both EPS and revenue, adding to concerns about near-term performance.

About USANA Health Sciences

USANA Health Sciences, Inc develops and sells nutritional supplements, healthy foods and personal-care products through a direct-selling business model. Its product portfolio includes vitamins and mineral supplements, meal-replacement and snack products, sports nutrition offerings, and skincare products marketed under the USANA and related brands.

Founded in 1992 by microbiologist and immunologist Myron W. Wentz, the company is headquartered in Salt Lake City, Utah. USANA distributes its products through a network of independent associates and preferred customers rather than primarily through traditional retail channels.

The company serves customers in markets across the Americas, Asia-Pacific and Europe, with a significant presence in countries including the United States, Canada, Australia, New Zealand, China, Hong Kong, Japan, South Korea, the Philippines, Singapore, Malaysia and Thailand.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.